SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001636050-19-000069
Filing Date
2019-08-09
Accepted
2019-08-09 06:56:20
Documents
53
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q a06301910qaxovant.htm 10-Q 1086434
2 EXHIBIT 10.1 a063019exhibit101.htm EX-10.1 114517
3 EXHIBIT 10.2 a063019exhibit102.htm EX-10.2 111924
4 EXHIBIT 31.1 a063019exhibit311.htm EX-31.1 10214
5 EXHIBIT 31.2 a063019exhibit312.htm EX-31.2 10192
6 EXHIBIT 32.1 a063019exhibit321.htm EX-32.1 6335
7 EXHIBIT 32.2 a063019exhibit322.htm EX-32.2 6250
  Complete submission text file 0001636050-19-000069.txt   3920834

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT axon-20190630.xml EX-101.INS 405134
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT axon-20190630.xsd EX-101.SCH 34959
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT axon-20190630_cal.xml EX-101.CAL 51916
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT axon-20190630_def.xml EX-101.DEF 162208
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT axon-20190630_lab.xml EX-101.LAB 438678
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT axon-20190630_pre.xml EX-101.PRE 258420
Mailing Address 11 TIMES SQUARE 33RD FLOOR NEW YORK NY 10036
Business Address 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB 44 203 318 9708
Axovant Gene Therapies Ltd. (Filer) CIK: 0001636050 (see all company filings)

IRS No.: 981333697 | Fiscal Year End: 0331
Type: 10-Q | Act: 34 | File No.: 001-37418 | Film No.: 191011273
SIC: 2834 Pharmaceutical Preparations